Anti-Tissue Factor Antibody Conjugates for Targeted Payload Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods to modulate the activity of tissue factor (TF) and its downstream signaling coagulation processes, particularly in diseases such as thrombosis, atherosclerosis, and cancer, and for therapeutics that specifically target TF-expressing cells and tissues.
Innovation Solution
Development of antibodies and antibody conjugates that selectively bind to TF, which can be linked to payload moieties for targeted delivery to TF-expressing cells, including pharmaceutical compositions for parenteral administration, and methods for using these antibodies and conjugates for therapeutic, diagnostic, or analytical purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional coagulation modulators are used, then coagulation processes can be influenced, but specificity to TF-expressing cells is insufficient
Solution Approach 1:
The patent uses antibodies as intermediary molecules that specifically bind to tissue factor on target cells. This intermediary approach allows selective targeting of TF-expressing cells while modulating coagulation processes, resolving the contradiction between specificity and broad modulation capability
Solution Approach 2:
The invention employs antibodies with specific binding properties that concentrate therapeutic effect locally at TF-expressing sites. This local quality approach enables selective action on target cells while maintaining the ability to influence coagulation processes wherever TF is expressed
2Manufacturing precision
If non-specific coagulation modulators are used, then broad coagulation influence is achieved, but payload delivery precision to target cells is reduced
Solution Approach 1:
The patent merges the specific targeting capability of antibodies with therapeutic or diagnostic payloads. This combination achieves both precise payload delivery to TF-expressing cells and efficient modulation of coagulation processes through the unified antibody-payload conjugate
Solution Approach 2:
The antibody platform serves multiple functions: specific target cell recognition, payload delivery, and coagulation process modulation. This multi-functionality resolves the contradiction between delivery precision and overall process efficiency
3Object-affected harmful factors
If TF activity is inhibited, then thrombosis risk is reduced, but coagulation protection capability may be compromised
Solution Approach 1:
The patent extracts and selectively inhibits the pathological aspect of TF activity (thrombosis promotion) while preserving normal coagulation function. By targeting TF specifically on abnormal or activated cells, the invention reduces thrombosis risk without compromising essential coagulation protection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies and antibody conjugates effectively deliver payload moieties to TF-expressing cells, providing therapeutic benefits for conditions like cancer, autoimmune diseases, and infections, and enabling diagnostic and analytical methods, including tumor growth inhibition and payload delivery.
Implementation Method 1
antibodies that selectively bind tissue factor (TF)
Implementation Method 2
antibody conjugates that selectively bind TF. The antibody conjugates comprise an antibody that binds TF linked to one or more payload moieties
Data Source
AI summary
The present disclosure relates to antibodies and antibody conjugates that selectively bind to tissue factor and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies and antibody conjugates, such as therapeutic and diagnostic methods.